Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 16
1995 60
1996 77
1997 63
1998 72
1999 64
2000 75
2001 84
2002 84
2003 96
2004 96
2005 135
2006 184
2007 141
2008 162
2009 174
2010 162
2011 147
2012 131
2013 128
2014 139
2015 114
2016 129
2017 109
2018 97
2019 82
2020 75
2021 78
2022 65
2023 43
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

2,812 results

Results by year

Filters applied: . Clear all
Page 1
Bosentan.
Cheng JW. Cheng JW. Heart Dis. 2003 Mar-Apr;5(2):161-9. doi: 10.1097/01.hdx.0000061696.83820.51. Heart Dis. 2003. PMID: 12713683 Review.
In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance. ...In addition, bosentan is not only a substrate but also an inducer of CYP3A4 and CYP2C9. ...
In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolera …
Bosentan for idiopathic pulmonary fibrosis.
King TE Jr. King TE Jr. Curr Opin Investig Drugs. 2008 Nov;9(11):1171-9. Curr Opin Investig Drugs. 2008. PMID: 18951296 Review.
Endothelin-1 may underlie the pathogenesis of lung fibrosis, therefore it was hypothesized that the oral dual endothelin receptor antagonist bosentan may have efficacy for the treatment of IPF. The BUILD-1 study evaluated the efficacy, safety and tolerability of bosenta …
Endothelin-1 may underlie the pathogenesis of lung fibrosis, therefore it was hypothesized that the oral dual endothelin receptor antagonist …
Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N, Kilpatrick D. Dwyer N, et al. Future Cardiol. 2011 Jan;7(1):19-37. doi: 10.2217/fca.10.114. Future Cardiol. 2011. PMID: 21174507 Review.
Bosentan improves cardiopulmonary hemodynamics, exercise capacity, WHO functional class and quality of life, as well as delaying time to clinical worsening in patients with PAH. This article reviews the role of endothelin-1 in the pathogenesis and progression of PAH, the d …
Bosentan improves cardiopulmonary hemodynamics, exercise capacity, WHO functional class and quality of life, as well as delaying time …
Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M, Kodric M, Longo C, Vassallo FG. Confalonieri M, et al. Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1503-12. doi: 10.1586/erc.09.148. Expert Rev Cardiovasc Ther. 2009. PMID: 19954311 Review.
Nevertheless, bosentan has been shown to be safe and the data from most literature encourage its use for inoperable CTEPH. However, further randomized controlled trials are needed to definitively establish bosentan as a standard drug for CTEPH....
Nevertheless, bosentan has been shown to be safe and the data from most literature encourage its use for inoperable CTEPH. However, f …
Tracleer (bosentan).
Scarpa WJ Jr. Scarpa WJ Jr. J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):73. doi: 10.1111/j.1524-6175.2002.00748.x. J Clin Hypertens (Greenwich). 2002. PMID: 11821645 Free PMC article. Review. No abstract available.
From bosentan (Tracleer) to macitentan (Opsumit): The medicinal chemistry perspective.
Boss C, Bolli MH, Gatfield J. Boss C, et al. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3381-94. doi: 10.1016/j.bmcl.2016.06.014. Epub 2016 Jun 10. Bioorg Med Chem Lett. 2016. PMID: 27321813 Review.
Activation of the endothelin system plays a driving role in several chronic cardiovascular diseases and several endothelin receptor antagonists (ERAs) (bosentan (6), ambrisentan (83) and macitentan (43)) have successfully been introduced as oral treatments for the life thr …
Activation of the endothelin system plays a driving role in several chronic cardiovascular diseases and several endothelin receptor antagoni …
Persistent pulmonary hypertension of the newborn.
Mandell E, Kinsella JP, Abman SH. Mandell E, et al. Pediatr Pulmonol. 2021 Mar;56(3):661-669. doi: 10.1002/ppul.25073. Pediatr Pulmonol. 2021. PMID: 32930508 Review.
Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes.
Oorts M, Van Brantegem P, Deferm N, Chatterjee S, Dreesen E, Cooreman A, Vinken M, Richert L, Annaert P. Oorts M, et al. J Pharmacol Exp Ther. 2021 Oct;379(1):20-32. doi: 10.1124/jpet.121.000695. Epub 2021 Aug 4. J Pharmacol Exp Ther. 2021. PMID: 34349015
When exposed to 10 M CDCA, bosentan caused a shift from canalicular efflux to sinusoidal efflux of GCDCA. ...We confirmed the direct inhibitory effect of bosentan on CDCA conjugation with glycine in incubations with liver S9 fraction. ...
When exposed to 10 M CDCA, bosentan caused a shift from canalicular efflux to sinusoidal efflux of GCDCA. ...We confirmed the direct …
Bosentan in pediatric patients with pulmonary arterial hypertension.
Beghetti M. Beghetti M. Curr Vasc Pharmacol. 2009 Apr;7(2):225-33. doi: 10.2174/157016109787455653. Curr Vasc Pharmacol. 2009. PMID: 19356006 Review.
In the absence of controlled trials, these 21 studies represent the current evidence on the effectiveness and safety of bosentan in the treatment of pediatric PAH. Bosentan appears to improve long-term functional status and hemodynamics in children with PAH but impr …
In the absence of controlled trials, these 21 studies represent the current evidence on the effectiveness and safety of bosentan in t …
Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q, Guo N, Chen J, Parks D, Tian Z. Zhao Q, et al. J Clin Pharm Ther. 2022 Feb;47(2):146-156. doi: 10.1111/jcpt.13481. Epub 2021 Jul 28. J Clin Pharm Ther. 2022. PMID: 34319626 Review.
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no significant difference in 6MWD (MD: -1.32; 95% CI: -27.87, 25.31, SUCRA score: ambrisentan 0.73, bosentan 0.77), BDI (MD: -0.16; 95% …
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no …
2,812 results